- 著者
-
KITAZATO KENJI
TAKEDA SETSUO
UNEMI NORIO
- 出版者
- 公益社団法人日本薬学会
- 雑誌
- Journal of pharmacobio-dynamics (ISSN:0386846X)
- 巻号頁・発行日
- vol.5, no.10, pp.803-810, 1982-10
1,3,3,5,5-Pentaziridino-1-thia-2,4,6-traiza-3,5-diphosphorine-1-oxide (SOAz), a new antitumor agent, was evaluated for antitumor activity against various mouse- and rattumor systems. The optimal treatment regimens of SOAz (i.p.) gave 262% and 134% increase in life span (ILS) in mice P338 leukemia and L1210 leukemia implanted intraperitoneally, respectively, and 239% ILS in rats with Yoshida sarcoma of which 86% survived for 60 d after intraperitoneal tumor implantation. The compound showed a definite activity against Lewis lung carcinoma implanted intravenously. The compound also exhibited 80-100% inhibition of tumor local growth in all of four experimental tumor systems used in the present study. In contrast to cyclophosphamide, SOAz was active against B16 melanoma and Meth A, and demonstrated high activity against a subline of L1210 leukemia resistant to cyclophosphamide.